Timing is everything

Citation for published version:
https://doi.org/10.1016/j.xcrm.2022.100725

Digital Object Identifier (DOI):
10.1016/j.xcrm.2022.100725

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Cell Reports Medicine

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Spinal muscular atrophy (SMA) arises from homozygous loss of the Survival Motor Neuron 1 (SMN1) gene. This causes degeneration of lower motor neurons and muscle atrophy, as well as an array of systemic defects. In most cases, patients suffer from the severe subtype of the disease, SMA type I. Without treatment, symptoms present within six months after birth and no major motor milestone is reached. Historically, infants would not survive past the age of two. Humans have an additional copy of SMN1, called SMN2, which is alternatively spliced and only produces about ten percent of the full-length, functional SMN protein. Copy number of SMN2 varies in SMA patients, making this gene an important modifier of disease severity.

The past decade has brought tremendous therapeutic advances for treating SMA. Three therapies are now available, each with a distinct mechanism of action and delivery strategy, and each providing a precious disease-modifying treatment. Nusinersen (Spinraza), an antisense oligonucleotide targeting SMN2, was approved by the FDA in December 2016. Onasemnogene abeparvovec (Zolgensma) was approved a couple of years later and is a gene-replacement therapy. Also targeting SMN2, the small molecule risdiplam (Evrysdi) is the most recently approved SMN-dependent therapy for SMA. The elevated price tag of these treatments (>$340,000 per year for Evrysdi) is in part justified by their lifesaving and life-quality-improving capacity. While patients who respond well to treatment reach motor milestones never thought possible, benefits can vary widely. Now that such treatments are available, important questions surrounding the optimal timing and route of administration need to be addressed.

A growing number of studies indicate that SMA has a strong developmental component. Indeed, the SMN protein is crucial for—and expressed at high levels throughout—development in the nervous system, with levels decreasing after birth. A wealth of preclinical data has shown that the therapeutic time-window to treat SMA is narrow. Pathological defects have been described prenatally and point to developmental phenomena underlying motor neuron degeneration and systemic phenotypes. In mouse models, early treatment increases the chances of extending survival and improving motor functions. In the clinic, interim results from the phase II NURTURE trial already provided precious information confirming this effect in SMA patients. Starting nusinersen treatment pre-symptomatically in infants with two or three copies of SMN2 provided significantly improved outcomes compared to treatment initiated in symptomatic patients.

Twin papers published in Nature Medicine in June 2022 describe the results of SPR1NT, a phase III clinical trial for onasemnogene abeparvovec. This single-dose intravenous gene-replacement therapy delivers an SMN1 transgene using a modified AAV9 vector. In SPR1NT, the treatment was tested for safety and efficacy in pre-symptomatic infants at risk of developing SMA type I or II (with two or three copies of SMN2, respectively). This study follows up the original trial for onasemnogene abeparvovec in 15 symptomatic SMA type I patients. Following prenatal or newborn genetic confirmation of biallelic deletion of SMN1, 14 infants with two copies of SMN2 and 15 infants with three copies of SMN2 were treated at ≤6 weeks of life, before symptom onset. The results from SPR1NT show that neonates treated pre-symptomatically achieved greater and earlier developmental milestones than untreated patients and patients treated once symptomatic. While the cohorts were small, the findings are unequivocal: treatment needs to be started as early as possible to maximize therapeutic benefits.

Newborn screening (NBS) is likely to be key for the delivery of such early treatment, but many countries who have the therapies available do not yet include SMA in their NBS programs. Australia, Belgium, Canada, Germany, Italy, Japan, and Taiwan have all implemented NBS programs for SMA as have 46 states in the US. All infants included in the SPR1NT trial were screened by NBS or prenatal testing. As well as increasing therapeutic efficacy, another benefit of pre-symptomatic treatment—and thus NBS—may be to alleviate the high financial costs arising from living with severe
SMA. For example, one study investigating Australian NBS programs revealed that the cost of NBS coupled with early gene therapy fell well within accepted thresholds for willingness-to-pay.10

The publications by Strauss et al. provide the first direct clinical evidence that pre-symptomatic treatment with gene therapy enhances its therapeutic efficacy in infants with SMA type I and II. This should encourage the SMA community and stakeholders to consider pre-symptomatic timing as optimal for therapy delivery and provide support to convince policy makers of the importance and value of NBS for SMA.

DECLARATION OF INTERESTS

T.H.G. has provided consultancy and advisory services concerning SMA therapies to Roche and Novartis. T.H.G. is chair of the clinical & scientific advisory board of SMA Europe.

REFERENCES


